Xcout Intel
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, focused on developing RNA-interference therapeutic interventions for neurodegenerative diseases. The company launched with significant venture backing from life sciences investors.
Subscribe to see Atalanta Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Atalanta Therapeutics at a glance
Atalanta Therapeutics is a biotechnology company headquartered in United States. It has raised at least $207M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $97M in January 2025. Xcout tracks 5 named people at Atalanta Therapeutics, including Alicia Secor (Former CEO).
Atalanta Therapeutics leadership
- Alicia SecorFormer CEO
- Joanne KotzChief Executive Officer
- Doug PagánChief Financial Officer & Chief Operating Officer
- Alicia Secorfounder
- Stephen KnightPresident and Senior Managing Partner of F-Prime and a member of the Atalanta Board of Directors
Atalanta Therapeutics funding rounds
At least $207M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $97M | 9 named | |
| Series A | $110M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Atalanta Therapeutics competitors
A few of Atalanta Therapeutics's closest competitors — see the full list of competitors and alternatives →
City Therapeutics, Inc. is a privately held biopharmaceutical company headquartered in Cambridge, Massachusetts, leading the future of RNA interference therapeutics. The company announced its launch with a $135 million Series A financing and has established strategic research collaborations with partners like Biogen.
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Rgenta Therapeutics, Inc. is a biotechnology research company headquartered in Woburn, Massachusetts, that focuses on unlocking the therapeutic potential of disease-relevant RNA targets.
Argo Therapeutics is a Swiss biotechnology company headquartered in Allschwil, Switzerland, focused on neurodegenerative-disease therapeutics.
Harness Therapeutics Ltd. is a biotechnology company founded in 2023 and based in Cambridge, United Kingdom. The company focuses on RNA biology and the development of novel therapeutics for the treatment of neurodegenerative diseases.
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Get Atalanta Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Atalanta Therapeutics in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access